Abstract 2270
Background
Despite a population of over 180 million and over 115,950 new cases of cancer diagnosed every year, Nigeria has no dedicated medical oncologists (MO). Most oncology care is delivered through surgical (SO) and radiation oncologists (RO) who number less than 50 in the entire country. With the limited number of oncology professionals, cancer patients experience poor outcomes, with a less than 10% of 5-year cancer survival rate.
Methods
The participants were nominated by their institutions to attend the medical oncology training. Through the support of FSP and U.S. Embassy in Nigeria, MGM and TOC delivered 10-days of lectures based on ASCO, ESMO and NCCN guidelines in Abuja, Nigeria. Participants represented 15 Nigerian states, including 5 of the 6 ethnic and geographic regions. Mean correct scores of participants that completed both the pre- and post-course 25 question tests (composed by 2 of the authors TOC and MGM) were compared using GraphPad Prism 7.0a by Paired t-tests.
Results
Forty-four oncologists were identified of which 11 (25%) were females. Twenty-five (57%) completed both the pre- and post-tests and fully participated in the 10-day lecture series. 12 participates that completed the training were residents and 12 were attending physicians. One doctor did not identify as a resident or attending. Of the 25 that completed both tests, percentage of correct answers increased from 45% to 59% (2-sided p-value <0.0001). Benefits were seen both with attending doctors 45% to 59% (p = 0.0046) and resident doctors 45% to 59% (0.0007).
Conclusions
MO education coordinated by FSP and PPB improved MO knowledge in Nigeria regardless of participant background. Similar models may be employed across Sub-Saharan Africa. Reasons for lost participation need to be defined.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Project PinkBlue.
Funding
United States of America Department of State.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract